AI Verdict
HIT has stronger fundamentals based on our AI analysis.
HIT vs HGYN Fundamental Comparison
| Metric | HIT | HGYN |
|---|---|---|
| Revenue | $33.3M | $612,206.0 |
| Net Income | $1.3M | $116,163.0 |
| Net Margin | 3.8% | 19.0% |
| ROE | 7.5% | N/A |
| ROA | 5.5% | 27.0% |
| Current Ratio | 3.13x | 0.85x |
| Debt/Equity | 0.00x | N/A |
| EPS | $0.02 | $0.00 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
HIT vs HGYN: Frequently Asked Questions
Is HIT or HGYN a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), HIT has stronger fundamentals. HIT is rated SELL (72% confidence) while HGYN is rated STRONG SELL (90% confidence). This is not investment advice.
How does HIT compare to HGYN fundamentally?
Health In Tech, Inc. has ROE of 7.5% vs HONG YUAN HOLDING GROUP's N/A. Net margins are 3.8% vs 19.0% respectively.
Which stock pays higher dividends, HIT or HGYN?
HIT has a dividend yield of N/A or no dividend while HGYN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in HIT or HGYN for long term?
For long-term investing, consider that HIT has SELL rating with 72% confidence, while HGYN has STRONG SELL rating with 90% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about HIT vs HGYN?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For HIT vs HGYN, the AI consensus favors HIT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.